ערך בספרים למניה: Rani Therapeutics Inc (RANI)

Rani Therapeutics is developing the innovative RaniPill capsule, which replaces injections with intestinal micro-injections. The book value per share reflects the dynamics of equity, with the most recent value recorded as 0.35. Future success depends on drug bioavailability, while pricing power and licensing revenues will become available to the company upon the completion of clinical trials.

A conservative approach requires an assessment of the company's actual net assets to determine its intrinsic value. This metric is calculated as the difference between all assets and liabilities divided by the number of shares; by analyzing the book value per share chart, an investor can see the capital depletion of Rani Therapeutics (RANI) resulting from a lack of revenue and the costs associated with clinical trials of robotic capsules.